| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 28 | 41.6x | 17.8x | Bottom tier | |
Growth | 73 | 10.3% | 7.1% | Top tier | |
Quality | 77 | 22.5% | 4.5% | Top tier | |
Safety | 90 | — | 2.6x | Top tier | |
Capital Return | 49 | — | 2.12% | Around median | |
Momentum | 96 | 55.6% | 2.9% | Top tier | |
Sentiment | 75 | 6 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Guardian Pharmacy Services operates a network of long-term care pharmacies serving residents and healthcare facilities across multiple local markets. Revenue growth is tied to increases in resident and prescription counts, expansion of the facility base, acquisitions, higher resident medication needs, plan optimization, and product and payer mix. At the end of fiscal Q2 2026, the number of residents served exceeded 210 thousand, growing year over year in the upper single digits, while prescription volume increased at the same rate.
In fiscal Q2 2026, the company reported revenue of $351.2 million according to the earnings call, up 2% year over year, while EDGAR data showed revenue of $351.8 million. Gross profit reached $80.0 million, up 18%, and gross margin reached 22.8%, while adjusted EBITDA was $29.7 million, up 19%, with a margin of 8.4%. The company reported net income of $22.1 million on the earnings call, including an $8.5 million settlement of a dispute with a payer, compared with $8.8 million in the comparable period; EDGAR data reports net income of $21.9 million.
The mix of results reflects a clear divergence between operating growth and reported revenue growth: reported revenue increased only 2% due to IRA-related price reductions, but would have grown at a low-double-digit rate without those reductions. Organic growth, acquisitions, higher resident needs, plan optimization, and a favorable product and payer mix helped lift profitability, while margins also benefited from purchasing power, improved labor productivity, and support infrastructure efficiency.
Automated analysis for informational purposes only — not investment advice.
The average analyst target is $45.33, within a relatively wide range of $40 to $49, with a “Buy” consensus; the average is approximately 3.6% below the 52-week range high of $47.02, while the highest target exceeds that high. No displayed price-to-earnings ratio is available for the stock, making the target range and operating results more useful than an earnings multiple in assessing it; on the other hand, the raised fiscal 2026 outlook should be weighed against the expected decline in reported revenue during its second half and the risk of increased supply following the conversion of Class B shares.
Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.
Revenue was $351.2 million according to the earnings call, up 2% year over year, and would have grown at a low-double-digit rate without IRA price reductions. Gross profit increased 18% to $80.0 million, and gross margin reached 22.8%. Organic growth, acquisitions, higher resident needs, plan optimization, and a favorable product and payer mix contributed to this result.
IRA-related price reductions pressured reported revenue, limiting growth in the first half of fiscal 2026 to 2%, although growth would have been in the low double digits without them. Management expects reported revenue in the second half of fiscal 2026 to decline year over year in the low single digits, versus underlying growth in the upper single digits when excluding the reductions. On August 6, 2026, management said it was comfortable with its ability to mitigate the margin impact of the next tranche, but the estimated revenue impact of approximately 40% of the 2026 tranche remained preliminary.
The company raised its expected revenue range to $1.43–$1.45 billion from $1.40–$1.42 billion. It also raised its adjusted EBITDA range to $129–$131 million from $123–$127 million. This outlook does not include contributions from future acquisitions, while it includes a limited contribution from the two smaller acquisitions completed during fiscal 2026.
After the end of fiscal Q2 2026, Guardian announced its acquisition of Wellness Concepts, a long-term care pharmacy in the Shenandoah Valley of Virginia. It also launched a new location in Lexington representing its first facility in Kentucky, with support from existing pharmacies in Tennessee, Cincinnati, and neighboring areas. Management estimates that acquired and new locations typically require approximately four years to reach the company’s average profitability, making them a long-term growth driver with a margin-dilutive impact during the expansion phase.
Yes, adjusted EBITDA increased 23% in the first half of fiscal 2026 and rose 19% in Q2 to $29.7 million. Adjusted EBITDA margin was 8.4%, despite a reduction of approximately 60 basis points in consolidated margin due to 2024 and 2025 acquisitions and locations. The improvement was driven by greater purchasing power, better labor productivity, and higher support infrastructure efficiency, while fuel costs remained a source of pressure.
The company ended fiscal Q2 2026 with approximately $90 million in cash, compared with approximately $65 million in the previous quarter, and no debt according to the question-and-answer session. Management said cash conversion returned to a more typical level after the working-capital reset related to IRA implementation in fiscal Q1 2026. Acquisitions and new locations remain priorities for the use of liquidity, while the company retains financial flexibility in case opportunities related to Omnicare assets emerge, with no impact from them included in the fiscal 2026 outlook.
